OUR PRODUCTS
Biologics
Innovative therapies derived from living organisms, including monoclonal antibodies, recombinant proteins, and cell-based treatments. Our focus lies in developing and advancing biologics to target complex and chronic diseases with high precision and efficacy.
Biosimilars
High-quality, cost-effective alternatives to original biologic therapies. We specialize in developing biosimilars that match reference products in safety, efficacy, and quality—expanding access to advanced treatments worldwide.
Novel Peptides
Cutting-edge peptide-based therapeutics designed to modulate biological functions with high specificity and low toxicity. We focus on innovative peptide discovery and development for unmet medical needs across various therapeutic areas.
Oligonucleotides
Next-generation nucleic acid therapies engineered to modulate gene expression at the molecular level. Our pipeline includes antisense oligonucleotides, siRNA, and other RNA-based modalities targeting genetic and rare diseases.
Oncology
Dedicated to advancing cancer care through innovative therapeutics that target tumor biology with precision. Our oncology portfolio includes biologics, targeted therapies, and novel modalities aimed at improving survival and quality of life for cancer patients.
Orphan Drugs
Specialized treatments for rare and underserved diseases with limited or no existing therapies. We are committed to addressing critical gaps in care by developing and delivering life-changing solutions for patients with rare conditions.